Status: Not yet recruiting
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Participants needed: 12
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: MingSight Pharmaceuticals, IncUpdated: Sep 29, 2025
Eligibility criteria
Age 18 years or older. [+2]
Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma. [+1]